Evidence map›Paper›PMID 41609963›Full record

ArticleMedical oncology (Northwood, London, England)2026

Two-stage inertial microfluidics enrichment of activated T-cells towards a bead-less chimeric antigen receptor manufacturing protocol.

Mona T Elsemary, Michelle F Maritz, Louise E Smith, Majid Ebrahimi Warkiani, Benjamin Thierry

Abstract read
In one paragraph

Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mona T ElsemaryFuture Industries Institute, University of South Australia Mawson Lakes Campus, Mawson Lakes, SA, 5095, Australia.
Michelle F MaritzFuture Industries Institute, University of South Australia Mawson Lakes Campus, Mawson Lakes, SA, 5095, Australia.
Louise E SmithFuture Industries Institute, University of South Australia Mawson Lakes Campus, Mawson Lakes, SA, 5095, Australia.
Majid Ebrahimi WarkianiSchool of Biomedical Engineering, University of Technology Sydney, 2007, Broadway, Ultimo, NSW, Australia.
Benjamin ThierryFuture Industries Institute, University of South Australia Mawson Lakes Campus, Mawson Lakes, SA, 5095, Australia. benjamin.thierry@unisa.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CAR-T cell therapy is leading the way in the field of cancer cell immunotherapies due to its high success rates. However, the manufacturing of CAR-T cells remains complex and expensive. T-cell enrichment from patient apheresis starting material is a key step in the manufacture but cellular impurities interfere with the ex vivo transduction of T-cells and their proliferation. Current enrichment methods including magnetic bead selection suffer from various limitations. We report here a bead-less T-cell enrichment process through a two-stage procedure based on inertial microfluidics. Using apheresis like starting material samples from healthy donors, the dual-stage process showed an efficient 87% (SD ± 6%) enrichment and 80% (SD ± 30%) recovery of T-cells. Validation of the process with ovarian cancer samples resulted in a T-cell purity 70% (SD ± 10%) from a starting purity of 48% (SD ± 6%) at a 64% (SD ± 4%) T-cell recovery. The two-stage inertial microfluidic process was also shown to have no detectable effect on the proliferation of the cells.

Indexed as

Immunotherapy, AdoptiveMicrofluidicsReceptors, Chimeric AntigenT-LymphocytesCell SeparationFemaleHumansLymphocyte ActivationOvarian NeoplasmsReceptors, Chimeric AntigenChimeric antigen receptorImmunotherapyMicrofluidicsOvarian cancerT-cells

Identifiers

PMID41609963
PMCPMC12855359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.